What’s on Your Mind? Biomarkers for Alzheimer’s Disease -Emily Largent, JD, PhD, RN

When you hear ‘Alzheimer’s disease’ what comes to mind? Most people picture an older adult with dementia, but Alzheimer’s disease is rapidly being reconceptualized by researchers as a continuum that begins in a “preclinical” phase. Preclinical Alzheimer’s disease is characterized by the presence of biomarkers—amyloid plaques, tau tangles, and neurodegeneration—in the absence of cognitive impairment. The label offers insights into an individual’s risk of developing dementia years or even decades before the onset of clinically measurable cognitive impairment. In this talk, I will share research on how the preclinical label affects one’s sense of self, one’s family members, and even one’s future and argue that this is an area in which law and policy lag too far behind the rapidly evolving science.

Видео What’s on Your Mind? Biomarkers for Alzheimer’s Disease -Emily Largent, JD, PhD, RN канала Center for Bioethics and Social Sciences in Medicine